Peter B Mcintyre

List of Publications by Year
in descending order

314 papers	9,031 citations	57719 44 h-index	76872 74 g-index
325 all docs	325 docs citations	325 times ranked	7614 citing authors

#	Article	IF	Citations
1	Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA - Journal of the American Medical Association, 1997, 278, 925-931.	3.8	405
2	Corticosteroids for acute bacterial meningitis. The Cochrane Library, 2018, 2018, CD004405.	1.5	333
3	Effect of vaccines on bacterial meningitis worldwide. Lancet, The, 2012, 380, 1703-1711.	6.3	268
4	The changing and dynamic epidemiology of meningococcal disease. Vaccine, 2012, 30, B26-B36.	1.7	250
5	Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infectious Diseases, The, 2004, 4, 139-143.	4.6	216
6	Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program. Clinical Infectious Diseases, 2013, 57, 1427-1434.	2.9	178
7	Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatric Respiratory Reviews, 2008, 9, 201-212.	1.2	154
8	Rapid Increase in Pertactin-deficientBordetella pertussisIsolates, Australia. Emerging Infectious Diseases, 2014, 20, 626-33.	2.0	151
9	Corticosteroids for acute bacterial meningitis. , 2007, , CD004405.		125
10	Australia's national Q fever vaccination program. Vaccine, 2009, 27, 2037-2041.	1.7	117
11	National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatric Infectious Disease Journal, 2004, 23, 246-252.	1.1	105
12	Clinical relevance of TLR2, TLR4, CD14 and Fcî³RIIA gene polymorphisms in Streptococcus pneumoniae infection. Immunology and Cell Biology, 2008, 86, 268-270.	1.0	104
13	Anaphylaxis following quadrivalent human papillomavirus vaccination. Cmaj, 2008, 179, 525-533.	0.9	98
14	Acellular Pertussis Vaccine at Birth and One Month Induces Antibody Responses By Two Months of Age. Pediatric Infectious Disease Journal, 2010, 29, 209-215.	1.1	96
15	Corticosteroids for acute bacterial meningitis. , 2010, , CD004405.		96
16	Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Review of Vaccines, 2014, 13, 1081-1106.	2.0	96
17	The Australian Childhood Immunisation Registerâ€"A model for universal immunisation registers?. Vaccine, 2009, 27, 5054-5060.	1.7	95
18	Corticosteroids for acute bacterial meningitis. , 2013, , CD004405.		94

#	Article	IF	Citations
19	Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine, 2015, 33, 6277-6281.	1.7	93
20	Timeliness of childhood immunisation in Australia. Vaccine, 2006, 24, 4403-4408.	1.7	91
21	National Study of Adverse Reactions after Vaccination with Bacille Calmette-GuÃ©rin. Clinical Infectious Diseases, 2002, 34, 447-453.	2.9	89
22	Reduction in Hospitalizations for Pneumonia Associated With the Introduction of a Pneumococcal Conjugate Vaccination Schedule Without a Booster Dose in Australia. Pediatric Infectious Disease Journal, 2010, 29, 607-612.	1.1	89
23	Pertussis in early infancy: disease burden and preventive strategies. Current Opinion in Infectious Diseases, 2009, 22, 215-223.	1.3	87
24	Trends and patterns in vaccination objection, Australia, 2002â€“2013. Medical Journal of Australia, 2016, 204, 275-275.	0.8	82
25	Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia. Clinical Infectious Diseases, 2008, 46, 1647-1655.	2.9	79
26	A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Archives of Disease in Childhood, 2005, 90, 391-396.	1.0	76
27	Duration of Protection After First Dose of Acellular Pertussis Vaccine in Infants. Pediatrics, 2014, 133, e513-e519.	1.0	76
28	The Association of Respiratory Viruses, Temperature, and Other Climatic Parameters with the Incidence of Invasive Pneumococcal Disease in Sydney, Australia. Clinical Infectious Diseases, 2006, 42, 211-215.	2.9	72
29	Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. Journal of Infectious Diseases, 2015, 211, 91-99.	1.9	71
30	Long-term Impact of a â€œ3 + 0â€•Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002â€“2014. Clinical Infectious Diseases, 2017, 64, 175-183.	2.9	70
31	Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bulletin of the World Health Organization, 2014, 92, 593-604.	1.5	67
32	Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine, 2011, 9, 104.	2.3	66
33	Increased Population Prevalence of Low Pertussis Toxin Antibody Levels in Young Children Preceding a Record Pertussis Epidemic in Australia. PLoS ONE, 2012, 7, e35874.	1.1	66
34	Chemotherapy in giardiasis: Clinical responses and in vitro drug sensitivity of human isolates in axenic culture. Journal of Pediatrics, 1986, 108, 1005-1010.	0.9	63
35	MMR, Wakefield and The Lancet: what can we learn?. Medical Journal of Australia, 2010, 193, 5-7.	0.8	63
36	Parental Tdap Boosters and Infant Pertussis: A Case-Control Study. Pediatrics, 2014, 134, 713-720.	1.0	63

#	Article	IF	Citations
37	Prevention of serious bacterial infection in children with nephrotic syndrome. Journal of Paediatrics and Child Health, 1998, 34, 314-317.	0.4	61
38	Reactogenicity and immunogenicity of a live attenuated tetravalent measlesâ€“mumpsâ€“rubellaâ€“varicella (MMRV) vaccine. Vaccine, 2002, 21, 281-289.	1.7	58
39	Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6â€“18 Months Old. Journal of Infectious Diseases, 2004, 189, 462-470.	1.9	53
40	Survey of pertussis morbidity in adults in western Sydney. Medical Journal of Australia, 2000, 173, 74-76.	0.8	52
41	Genomic dissection of Australian Bordetella pertussis isolates from the 2008â€“2012 epidemic. Journal of Infection, 2016, 72, 468-477.	1.7	52
42	Elimination of endemic measles tranmission in Australia. Bulletin of the World Health Organization, 2009, 87, 64-71.	1.5	51
43	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011â€“2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	51
44	The impact of adolescent pertussis immunization, 2004â€“2009: lessons from Australia. Bulletin of the World Health Organization, 2011, 89, 666-674.	1.5	48
45	Predictors of Disease Severity in Children Hospitalized for Pertussis During an Epidemic. Pediatric Infectious Disease Journal, 2015, 34, 339-345.	1.1	48
46	PERTUSSIS VACCINE EFFECTIVENESS AFTER MASS IMMUNIZATION OF HIGH SCHOOL STUDENTS IN AUSTRALIA. Pediatric Infectious Disease Journal, 2009, 28, 152-153.	1.1	47
47	Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people. Vaccine, 2008, 26, 5633-5640.	1.7	46
48	Pertussis in Older Adults: Prospective Study of Risk Factors and Morbidity. Clinical Infectious Diseases, 2012, 55, 1450-1456.	2.9	46
49	Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. Clinical Infectious Diseases, 2019, 68, 940-948.	2.9	46
50	BRASILIAN PURPURIC FEVER IN CENTRAL AUSTRALIA. Lancet, The, 1987, 330, 112.	6.3	44
51	Rotavirus gastroenteritis: impact on young children, their families and the health care system. Medical Journal of Australia, 1997, 167, 304-307.	0.8	44
52	Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine, 2010, 28, 2648-2652.	1.7	44
53	The Spectrum and Management of Otitis Media in Australian Indigenous and Nonindigenous Children: A National Study. Pediatric Infectious Disease Journal, 2007, 26, 689-692.	1.1	43
54	The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine, 2004, 22, 1138-1149.	1.7	42

#	Article	IF	Citations
55	Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine, 2004, 23, 132-138.	1.7	42
56	Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiology and Infection, 2004, 132, 185-193.	1.0	42
57	Tetanus in the elderlyâ€"An important preventable disease in Australia. Vaccine, 2007, 25, 1304-1309.	1.7	42
58	The Impact of Pneumococcal Conjugate Vaccine on Rates of Myringotomy With Ventilation Tube Insertion in Australia. Pediatric Infectious Disease Journal, 2009, 28, 761-765.	1.1	42
59	Immunisation coverage in Australia corrected for underâ€reporting to the Australian Childhood Immunisation Register. Australian and New Zealand Journal of Public Health, 2003, 27, 533-538.	0.8	41
60	Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group. Communicable Diseases Intelligence Quarterly Report, 2007, 31, 205-15.	0.6	41
61	Effectiveness of the linkage of child care and maternity payments to childhood immunisation. Vaccine, 2004, 22, 2345-2350.	1.7	40
62	Epiglottitis in Sydney before and after the introduction of vaccination againstHaemophilus influenzaetype b disease. Internal Medicine Journal, 2005, 35, 530-535.	0.5	40
63	Improving uptake of MMR vaccine. BMJ: British Medical Journal, 2008, 336, 729-730.	2.4	40
64	Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study. Vaccine, 2016, 34, 3967-3971.	1.7	40
65	Neonatal Immunization: Rationale, Current State, and Future Prospects. Frontiers in Immunology, 2018, 9, 532.	2.2	40
66	Health care incentives in immunisation. Australian and New Zealand Journal of Public Health, 1999, 23, 285-288.	0.8	39
67	Epidemiology of invasive meningococcal B disease in Australia, 1999â€"2015: priority populations for vaccination. Medical Journal of Australia, 2017, 207, 382-387.	0.8	39
68	Higher pertussis hospitalization rates in indigenous Australian infants, and delayed vaccination. Vaccine, 2007, 25, 588-590.	1.7	38
69	A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly. PLoS ONE, 2014, 9, e94578.	1.1	38
70	Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatrics, 2017, 171, 992.	3.3	37
71	Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine, 2004, 22, 2181-2191.	1.7	36
72	Vaccines for older adults. BMJ, The, 2021, 372, n188.	3.0	36

#	Article	IF	Citations
73	<scp>P</scp>aediatric <scp>A</scp>ctive <scp>E</scp>nhanced <scp>D</scp>isease <scp>S</scp>urveillance: A new surveillance system for <scp>A</scp>ustralia. Journal of Paediatrics and Child Health, 2013, 49, 588-594.	0.4	35
74	Global Childhood Deaths From Pertussis: A Historical Review. Clinical Infectious Diseases, 2016, 63, S134-S141.	2.9	35
75	Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clinical Infectious Diseases, 2018, 67, 367-374.	2.9	35
76	Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine, 2007, 25, 3574-3580.	1.7	34
77	Pertussis in infants: Preventing deaths and hospitalisations in the very young. Journal of Paediatrics and Child Health, 2008, 44, 161-165.	0.4	34
78	Changes in Patterns of Hospitalized Children With Varicella and of Associated Varicella Genotypes After Introduction of Varicella Vaccine in Australia. Pediatric Infectious Disease Journal, 2013, 32, 530-537.	1.1	34
79	Declining measles antibodies in the era of elimination: Australiaâ€™s experience. Vaccine, 2018, 36, 507-513.	1.7	34
80	Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth. JAMA Pediatrics, 2018, 172, 1045.	3.3	34
81	Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatric Infectious Disease Journal, 2003, 22, 956-959.	1.1	33
82	High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine, 2004, 23, 380-385.	1.7	33
83	The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine, 2007, 25, 8637-8641.	1.7	33
84	Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiology and Infection, 2015, 143, 2871-2881.	1.0	33
85	Factors associated with influenza vaccination in middle and older aged Australian adults according to eligibility for the national vaccination program. Vaccine, 2015, 33, 3299-3305.	1.7	33
86	Vaccine Preventable Diseases and Vaccination Policy for Indigenous Populations. Epidemiologic Reviews, 2006, 28, 71-80.	1.3	32
87	Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. The Cochrane Library, 2014, , CD001833.	1.5	32
88	The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. Journal of Infection, 2016, 72, 171-178.	1.7	32
89	The emergence of resistant pneumococcal meningitis--implications for empiric therapy. Archives of Disease in Childhood, 2002, 87, 207-210.	1.0	31
90	The importance of pertussis in older adults: A growing case for reviewing vaccination strategy in the elderly. Vaccine, 2012, 30, 6745-6752.	1.7	31

#	Article	IF	Citations
91	HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. Journal of Clinical Virology, 2014, 60, 250-256.	1.6	31
92	Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill & Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries. Clinical Infectious Diseases, 2016, 63, S123-S133.	2.9	31
93	Prevention of Neonatal Group B Streptococcal Sepsis: Is Routine Antenatal Screening Appropriate. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 120-126.	0.4	30
94	Varicella vaccination in Australia. Journal of Paediatrics and Child Health, 2005, 41, 544-552.	0.4	30
95	Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: Immunogenicity 5 years post-vaccination. Vaccine, 2009, 27, 1062-1066.	1.7	30
96	Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: The Australian experience. Vaccine, 2013, 31, 1964-1969.	1.7	30
97	No Jab, No Pay and vaccine refusal in Australia: the jury is out. Medical Journal of Australia, 2017, 206, 381-383.	0.8	30
98	Health care financing systems for increasing utilisation of tobacco dependence treatment. The Cochrane Library, 2003, , CD004405.	1.5	29
99	Cutaneous infection with Mycobacterium gordonae. Journal of Infection, 1987, 14, 71-78.	1.7	28
100	Current epidemiology of rubella and congenital rubella syndrome in Australia: Progress towards elimination. Vaccine, 2012, 30, 4073-4078.	1.7	28
101	Immunisation coverage reporting through the Australian Childhood Immunisation Register â€" an evaluation of the third-dose assumption. Australian and New Zealand Journal of Public Health, 2000, 24, 17-21.	0.8	27
102	Varicella seroprevalence and vaccine uptake in preschool children. Medical Journal of Australia, 2005, 182, 42-42.	0.8	27
103	When science is not enough â€" a risk/benefit profile of thiomersal-containing vaccines. Expert Opinion on Drug Safety, 2006, 5, 17-29.	1.0	27
104	SEVERE PERTUSSIS IN INFANTS. Pediatric Infectious Disease Journal, 2011, 30, 161-163.	1.1	27
105	Effectiveness of pertussis vaccination in New South Wales, Australia, 1996â€"1998. European Journal of Epidemiology, 2002, 18, 63-69.	2.5	26
106	Pneumonia in Elderly Australians: Reduction in Presumptive Pneumococcal Hospitalizations but No Change in All-Cause Pneumonia Hospitalizations Following 7-Valent Pneumococcal Conjugate Vaccination. Clinical Infectious Diseases, 2015, 61, 927-933.	2.9	26
107	Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort study. Vaccine, 2018, 36, 4062-4069.	1.7	26
108	Reasons for incomplete immunisation among Australian children. A national survey of parents. Australian Family Physician, 2004, 33, 568-71.	0.5	26

#	Article	IF	Citations
109	The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. Vaccine, 2012, 30, 7309-7314.	1.7	25
110	Defining long-term drivers of pertussis resurgence, and optimal vaccine control strategies. Vaccine, 2015, 33, 5794-5800.	1.7	25
111	Public opponents of vaccination: a case study. Vaccine, 2003, 21, 4700-4703.	1.7	24
112	The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiology and Infection, 2006, 134, 1208-1216.	1.0	24
113	Implementation of mandatory immunisation of healthcare workers: Observations from New South Wales, Australia. Vaccine, 2011, 29, 2895-2901.	1.7	24
114	Clinical epidemiology and predictors of outcome in children hospitalised with influenza A(H1N1)pdm09 in 2009: a prospective national study. Influenza and Other Respiratory Viruses, 2014, 8, 636-645.	1.5	24
115	Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Journal of Paediatrics and Child Health, 1996, 32, 211-217.	0.4	23
116	Evaluation of a protocol for selective empiric treatment of fever without localising signs. Archives of Disease in Childhood, 1997, 76, 129-133.	1.0	23
117	An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Australian Journal of Public Health, 1994, 18, 394-400.	0.2	23
118	Editorial Commentary: The "How" of Polymerase Chain Reaction Testing for Bordetella pertussis Depends on the "Why". Clinical Infectious Diseases, 2013, 56, 332-334.	2.9	23
119	Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine, 2017, 35, 345-352.	1.7	23
120	Immunogenicity of the reduced-antigen-content dTpa vaccine (BoostrixÂ®) in adults 55 years of age and over: A sub-analysis of four trials. Vaccine, 2011, 29, 5932-5939.	1.7	22
121	Systematic review of reporting rates of adverse events following immunization: An international comparison of post-marketing surveillance programs with reference to China. Vaccine, 2013, 31, 603-617.	1.7	22
122	Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. BMJ Open, 2015, 5, e007247-e007247.	0.8	22
123	Association between body mass index and laboratory-confirmed influenza in middle aged and older adults: a prospective cohort study. International Journal of Obesity, 2018, 42, 1480-1488.	1.6	22
124	The impact of vaccination against invasive Haemophilus influenzae type b disease in the Sydney region. Medical Journal of Australia, 1995, 162, 245-248.	0.8	22
125	Management of children with otitis media: A summary of evidence from recent systematic reviews. Journal of Paediatrics and Child Health, 2009, 45, 554-563.	0.4	21
126	A population based study. Medical Journal of Australia, 1993, 159, 766-772.	0.8	21

#	Article	IF	Citations
127	Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sexual Health, 2010, 7, 320.	0.4	20
128	Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4â€“6 years old. Vaccine, 2011, 29, 4230-4237.	1.7	20
129	Models of strategies for control of rubella and congenital rubella syndromeâ€”A 40 year experience from Australia. Vaccine, 2013, 31, 691-697.	1.7	20
130	Comparison of influenza vaccination coverage between immigrant and Australian-born adults. Vaccine, 2016, 34, 6388-6395.	1.7	20
131	Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine, 2018, 36, 2650-2656.	1.7	20
132	Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2004-2014.	2.0	20
133	Immunisation coverage annual report, 2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	20
134	Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infectious Diseases, 2015, 16, 52.	1.3	19
135	Vaccine preventable diseases in Australia, 2005 to 2007. Communicable Diseases Intelligence Quarterly Report, 2010, 34 Supp, S1-167.	0.6	19
136	Differing serologic responses to an Haemophilus influenzae type b polysaccharideâ€“Neisseria meningitidis outer membrane protein conjugate (PRPâ€“OMPC) vaccine in Australian Aboriginal and Caucasian infants â€” implications for disease epidemiology. Vaccine, 2000, 18, 2584-2591.	1.7	18
137	Predictors of Pneumococcal Vaccination Uptake in Hospitalized Patients Aged 65 Years and Over Shortly Following the Commencement of a Publicly Funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin, 2007, 3, 83-86.	2.4	18
138	Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. Journal of Infection, 2019, 78, 220-225.	1.7	18
139	Vaccines and the cold chain: is it too hotâ€¦ or too cold?. Medical Journal of Australia, 1999, 171, 82-82.	0.8	17
140	Evaluation of immunisation coverage for Aboriginal and Torres Strait Islander children using the Australian Childhood Immunisation Register. Australian and New Zealand Journal of Public Health, 2004, 28, 47-52.	0.8	17
141	Cough symptoms in children aged 5-14 years in Sydney, Australia: non-specific cough or unrecognized pertussis?. Respirology, 2005, 10, 359-364.	1.3	17
142	Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. , 2008, , CD001833.		17
143	Influenza Vaccine Safety in Children Less Than 5 Years Old. Pediatric Infectious Disease Journal, 2012, 31, 199-202.	1.1	17
144	Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012. Communicable Diseases Intelligence, 2014, 38, E179-94.	0.5	17

#	Article	IF	Citations
145	Influenza related hospitalisations in Sydney, New South Wales, Australia. Archives of Disease in Childhood, 2005, 91, 20-25.	1.0	16
146	Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine, 2010, 28, 2222-2226.	1.7	16
147	Impact of pneumococcal polysaccharide vaccine in people aged 65Âyears or older. Medical Journal of Australia, 2014, 200, 112-115.	0.8	16
148	Estimating the measles effective reproduction number in Australia from routine notification data. Bulletin of the World Health Organization, 2014, 92, 171-177.	1.5	16
149	Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine, 2014, 32, 759-765.	1.7	16
150	Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up. Vaccine, 2019, 37, 5016-5024.	1.7	16
151	Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians. Clinical Infectious Diseases, 2020, 70, 2607-2615.	2.9	16
152	Annual Immunisation Coverage Report 2016. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	16
153	Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Communicable Diseases Intelligence Quarterly Report, 2008, 32 Suppl, S2-67.	0.6	16
154	Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. Vaccine, 2009, 27, 313-318.	1.7	15
155	No evidence of increasingHaemophilus influenzaenon-b infection in Australian Aboriginal children. International Journal of Circumpolar Health, 2013, 72, 20992.	0.5	15
156	Intussusception After Monovalent Human Rotavirus Vaccine in Australia. Pediatric Infectious Disease Journal, 2014, 33, 959-965.	1.1	15
157	Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested caseâ€“control study. Vaccine, 2015, 33, 5647-5653.	1.7	15
158	Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. Vaccine, 2016, 34, 320-327.	1.7	15
159	Agreement between diagnoses of otitis media by audiologists and otolaryngologists in Aboriginal Australian children. Medical Journal of Australia, 2018, 209, 29-35.	0.8	15
160	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	0.5	15
161	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine, 2018, 36, 6307-6313.	1.7	14
162	Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study. The Lancet Child and Adolescent Health, 2019, 3, 713-724.	2.7	14

#	Article	IF	Citations
163	Delayed access to care and late presentations in children during the <scp>COVID</scp>â€19 pandemic New Zealandâ€wide lockdown: A New Zealand Paediatric Surveillance Unit study. Journal of Paediatrics and Child Health, 2021, 57, 1600-1604.	0.4	14
164	TYPHOID FEVER IN CHILDREN: DIAGNOSTIC AND THERAPEUTIC DIFFICULTIES. Pediatric Infectious Disease Journal, 1997, 16, 713-714.	1.1	14
165	Probabilistic linkage of national immunisation and state-based health records for a cohort of 1.9 million births to evaluate Australiaâ€™s childhood immunisation program. International Journal of Population Data Science, 2017, 2, 406.	0.1	14
166	Epidemiology of invasive pneumococcal disease in urban New South Wales, 1997â€“1999. Medical Journal of Australia, 2000, 173, S22-6.	0.8	13
167	Diagnostic testing and discharge coding for whooping cough in a children's hospital. Journal of Paediatrics and Child Health, 2003, 39, 586-590.	0.4	13
168	The relationship between pertussis symptomatology, incidence and serology in adolescents. Vaccine, 2008, 26, 5547-5553.	1.7	13
169	MODERN TRENDS IN MORTALITY FROM MENINGOCOCCAL DISEASE IN AUSTRALIA. Pediatric Infectious Disease Journal, 2009, 28, 1119-1120.	1.1	13
170	Adjunctive dexamethasone in meningitis: does value depend on clinical setting?. Lancet Neurology, The, 2010, 9, 229-231.	4.9	13
171	Risk factors and burden of acute Q fever in older adults in New South Wales: a prospective cohort study. Medical Journal of Australia, 2015, 203, 438-438.	0.8	13
172	Transiently increased IgE responses in infants and pre-schoolers receiving only acellular Diphtheriaâ€“Pertussisâ€“Tetanus (DTaP) vaccines compared to those initially receiving at least one dose of cellular vaccine (DTwP) â€“ Immunological curiosity or canary in the mine?. Vaccine, 2016, 34, 4257-4262.	1.7	13
173	Determining the contribution of Streptococcus pneumoniae to communityâ€acquired pneumonia in Australia. Medical Journal of Australia, 2017, 207, 396-400.	0.8	13
174	Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax, 2021, 76, 487-493.	2.7	13
175	Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence Quarterly Report, 2007, 31 Suppl, S1-152.	0.6	13
176	Occult pneumococcal bacteraemia and febrile convulsions.. BMJ: British Medical Journal, 1983, 286, 203-206.	2.4	12
177	Lumbar puncture in suspected neonatal sepsis. Journal of Paediatrics and Child Health, 1995, 31, 1-2.	0.4	12
178	Measles vaccination coverage among fiveâ€yearâ€old children: implications for disease elimination in Australia. Australian and New Zealand Journal of Public Health, 2003, 27, 413-418.	0.8	12
179	Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine, 2015, 33, 6666-6674.	1.7	12
180	Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine, 2017, 35, 4307-4314.	1.7	12

#	Article	IF	Citations
181	Australian rubella serosurvey 2012â€“2013: On track for elimination?. Vaccine, 2018, 36, 2794-2798.	1.7	12
182	Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6â€‰months: PREVIX_COMBO, a 3-arm randomised controlled trial. BMC Pediatrics, 2021, 21, 117.	0.7	12
183	Making influenza vaccination mandatory for health care workers: the views of NSW Health administrators and clinical leaders. NSW Public Health Bulletin, 2010, 21, 243.	0.3	12
184	Immunisation coverage annual report, 2008. Communicable Diseases Intelligence Quarterly Report, 2010, 34, 241-58.	0.6	12
185	Epidemiology and prevention of pneumococcal infections. Current Opinion in Pediatrics, 1997, 9, 9-13.	1.0	11
186	Measles in an era of measles control. Medical Journal of Australia, 2000, 172, 103-104.	0.8	11
187	Establishment of a surveillance system (utilising Midwifes Data Collection Systems) for monitoring the impact of hepatitis B vaccination on the population prevalence of chronic hepatitis B virus infection in Australia. Australian and New Zealand Journal of Public Health, 2008, 32, 272-275.	0.8	11
188	Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data. Vaccine, 2017, 35, 1524-1529.	1.7	11
189	Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort study. Vaccine, 2020, 38, 6057-6064.	1.7	11
190	Polio â€“ The old foe and new challenges: An update for clinicians. Journal of Paediatrics and Child Health, 2020, 56, 1527-1532.	0.4	11
191	Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6Âmonths: PREVIX_COMBO, a 3-arm randomised controlled trial. Vaccine: X, 2021, 7, 100086.	0.9	11
192	Immunisation coverage annual report, 2009. Communicable Diseases Intelligence Quarterly Report, 2011, 35, 132-48.	0.6	11
193	Conjugate pneumococcal vaccines for nonâ€indigenous children in Australia. Medical Journal of Australia, 2000, 173, S54-7.	0.8	10
194	Antibody and Cell-mediated Immunity to Pertussis 4 Years After Monovalent Acellular Pertussis Vaccine at Birth. Pediatric Infectious Disease Journal, 2014, 33, 511-517.	1.1	10
195	Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance. Clinical Infectious Diseases, 2017, 65, 827-832.	2.9	10
196	The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. Vaccine, 2018, 36, 1265-1271.	1.7	10
197	Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia. Vaccine, 2018, 36, 3533-3540.	1.7	10
198	Mapping immunisation coverage and conscientious objectors to immunisation in NSW. NSW Public Health Bulletin, 2003, 14, 8.	0.3	10

#	Article	IF	Citations
199	Immunisation and pregnancy: who, what, when and why?. Australian Prescriber, 2017, 40, 122-124.	0.5	10
200	Estimating immunisation coverage: is the 'third dose assumption' still valid?. Communicable Diseases Intelligence Quarterly Report, 2003, 27, 357-61.	0.6	10
201	Invasive Haemophilus influenzae type b disease in Australia: the beginning of the end?. Medical Journal of Australia, 1992, 156, 516-518.	0.8	9
202	Estimating the burden of pertussis in young children on hospitals and emergency departments: a study using linked routinely collected data. Epidemiology and Infection, 2014, 142, 695-705.	1.0	9
203	Human papillomavirus prevalence to age 60 years among Australian women prevaccination. Sexual Health, 2015, 12, 353.	0.4	9
204	â€˜Links2HealthierBubsâ€™ cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian women. BMJ Open, 2019, 9, e030277.	0.8	9
205	Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy. Epidemiology and Infection, 2019, 147, e118.	1.0	9
206	Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study. Clinical Infectious Diseases, 2020, 71, 340-350.	2.9	9
207	The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules. NSW Public Health Bulletin, 2011, 22, 224.	0.3	9
208	Australian vaccine preventable disease epidemiological review series: Influenza 2006 to 2015. Communicable Diseases Intelligence, 2016, 40, E482-E495.	0.5	9
209	Should Dexamethasone be Part of Routine Therapy of Bacterial Meningitis in Industrialised Countries?. , 2005, 568, 189-197.		8
210	Estimating Vaccine Coverage from Serial Trivariate Serologic Data in the Presence of Waning Immunity. Epidemiology, 2015, 26, 381-389.	1.2	8
211	Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia. Eurosurveillance, 2020, 25, .	3.9	8
212	Acute flaccid myelitis â€“ has it gone unrecognised in Australian children?. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	8
213	Immunisation coverage annual report, 2014. Communicable Diseases Intelligence, 2017, 41, E68-E90.	0.5	8
214	Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials. Lancet Infectious Diseases, The, 2022, 22, 1374-1387.	4.6	8
215	Rethinking contraindications to vaccination. Medical Journal of Australia, 1998, 168, 476-477.	0.8	7
216	The Population and Reproductive Health Programme in Brazil 1990-2002: Lessons Learned. Reproductive Health Matters, 2005, 13, 72-80.	1.3	7

#	Article	IF	Citations
217	Epidemiology of severe hepatitis A in Indigenous Australian children. Journal of Paediatrics and Child Health, 2007, 43, 383-387.	0.4	7
218	Long term population impact of seven-valent pneumococcal conjugate vaccine with a â€œ3+0â€³ scheduleâ€"How do â€œ2+1â€³ and â€œ3+1â€³ schedules compare?. Vaccine, 2015, 33, 3234-3241.	1.7	7
219	Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Communicable Diseases Intelligence Quarterly Report, 2003, 27, 324-41.	0.6	7
220	Immunisation coverage annual report, 2007. Communicable Diseases Intelligence Quarterly Report, 2009, 33, 170-87.	0.6	7
221	Immunisation coverage, 2012. Communicable Diseases Intelligence, 2014, 38, E208-31.	0.5	7
222	Vaccines: the new Australian bestâ€practice schedule. Medical Journal of Australia, 2004, 180, 494-496.	0.8	6
223	Using linked birth, notification, hospital and mortality data to examine false-positive meningococcal disease reporting and adjust disease incidence estimates for children in New South Wales, Australia. Epidemiology and Infection, 2015, 143, 2570-2579.	1.0	6
224	Vaccineâ€preventable child deaths in New South Wales from 2005 to 2014: How much is preventable?. Journal of Paediatrics and Child Health, 2018, 54, 356-364.	0.4	6
225	Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage. Vaccine, 2021, 39, 1727-1735.	1.7	6
226	Has pertussis increased in NSW over the past decade? An evaluation using hospitalisation and mortality data versus notifications 1988?2002. NSW Public Health Bulletin, 2003, 14, 71.	0.3	6
227	Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort. Pediatric Infectious Disease Journal, 2019, 38, 967-973.	1.1	6
228	Australia needs a vaccine injury compensation scheme: Upcoming COVID-19 vaccines make its introduction urgent. Australian Journal of General Practice, 2020, 49, .	0.3	6
229	Pertussis Disease and Antenatal Vaccine Effectiveness in Australian Children. Pediatric Infectious Disease Journal, 2022, 41, 180-185.	1.1	6
230	The outcome of childhood Haemophilus influenzae meningitis. A population based study. Medical Journal of Australia, 1993, 159, 766-72.	0.8	6
231	Position Paper: Chemoprophylaxis for Haemophilus and meningococcal infections. Journal of Paediatrics and Child Health, 1994, 30, 9-11.	0.4	5
232	Geographic differences in bacterial meningitis: Less may be as interesting as more. Journal of Paediatrics and Child Health, 1998, 34, 109-111.	0.4	5
233	A populationâ€based study of children with cerebral tuberculosis in New South Wales. Medical Journal of Australia, 1999, 171, 197-200.	0.8	5
234	Pertussis antibody levels in infants immunized with an acellular pertussis component vaccine, measured using whole-cell pertussis ELISA. Immunology and Cell Biology, 2000, 78, 254-258.	1.0	5

#	Article	IF	Citations
235	Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPaâ€“HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. International Journal of Infectious Diseases, 2010, 14, e41-e49.	1.5	5
236	Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older. Medical Journal of Australia, 2014, 201, 200-200.	0.8	5
237	Pertussis vaccine in pregnancyâ€”first dose for every infant?. Lancet, The, 2014, 384, 1484-1486.	6.3	5
238	Influence of Population Demography and Immunization History on the Impact of an Antenatal Pertussis Program. Clinical Infectious Diseases, 2016, 63, S213-S220.	2.9	5
239	Modeling the Effects of Priming With the Whole-Cell Bordetella Pertussis Vaccine. JAMA Pediatrics, 2016, 170, 1228.	3.3	5
240	Changing Patterns of Pertussis in a Children's Hospital in the Polymerase Chain Reaction Diagnostic Era. Journal of Pediatrics, 2016, 170, 161-165.e1.	0.9	5
241	High healthcare resource utilisation due to pertussis in Australian adults aged 65Âyears and over. Vaccine, 2020, 38, 3553-3559.	1.7	5
242	Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study. PLoS Medicine, 2021, 18, e1003733.	3.9	5
243	Guest Editorial: Lessons from surveillance?Solving the pertussis puzzle. NSW Public Health Bulletin, 2003, 14, 69.	0.3	5
244	Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Communicable Diseases Intelligence Quarterly Report, 2002, Suppl, i-xi, 1-111.	0.6	5
245	Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2008-2011. Communicable Diseases Intelligence, 2016, 40 Suppl, S1-70.	0.5	5
246	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011â€“2015. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	5
247	Severity of Rotavirus-Vaccine-Associated Intussusception: Prospective Hospital-Based Surveillance, Australia, 2007â€“2018. Pediatric Infectious Disease Journal, 2022, 41, 507-513.	1.1	5
248	Vaccines against invasive Haemophilus influenzae type b disease. Journal of Paediatrics and Child Health, 1994, 30, 14-18.	0.4	4
249	Pertussis re-emerging: who is responsible?. Australian and New Zealand Journal of Public Health, 1998, 22, 9-10.	0.8	4
250	Vaccines for other neonatal infections: Vaccination strategies for the prevention of neonatal pertussis. Expert Review of Vaccines, 2004, 3, 375-378.	2.0	4
251	Vaccination for the paediatrician. Journal of Paediatrics and Child Health, 2006, 42, 665-673.	0.4	4
252	Pertussis control: where to now?. Medical Journal of Australia, 2014, 200, 306-307.	0.8	4

#	Article	IF	Citations
253	Genetically modified pertussis toxin: a quantum leap?. Lancet Infectious Diseases, The, 2018, 18, 1169-1171.	4.6	4
254	Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: A record linkage cohort study. Vaccine, 2019, 37, 5835-5843.	1.7	4
255	10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial. BMJ Open, 2020, 10, e033511.	0.8	4
256	Comparing mortalities of the first wave of coronavirus disease 2019 (COVID-19) and of the 1918â€“19 winter pandemic influenza wave in the USA. International Journal of Epidemiology, 2021, 49, 2089-2091.	0.9	4
257	Immunisation Coverage Annual Report 2018. Communicable Diseases Intelligence (2018), 0, 45, .	0.3	4
258	Medicare Benefits Schedule data to monitor influenza immunisation in Australian adults. Public Health Research and Practice, 2015, 25, e2541543.	0.7	4
259	Lest we forget acute epiglottitis. Journal of Paediatrics and Child Health, 1998, 34, 306-7.	0.4	4
260	An evaluation of the Australian National Serosurveillance Program. Communicable Diseases Intelligence Quarterly Report, 2010, 34, 29-36.	0.6	4
261	Cellulitis in childhood invasive pneumococcal disease: A population-based study. Journal of Paediatrics and Child Health, 2006, 42, 354-358.	0.4	3
262	General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events. Vaccine, 2014, 32, 2204-2208.	1.7	3
263	Predicting localised measles outbreak potential in Australia. Vaccine, 2015, 33, 1176-1181.	1.7	3
264	Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program. Vaccine, 2018, 36, 4157-4160.	1.7	3
265	Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia. Pediatric Infectious Disease Journal, 2019, 38, 860-865.	1.1	3
266	Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine. Vaccine, 2020, 38, 2572-2577.	1.7	3
267	ULCERATIVE LESION OF THE NASAL BRIDGE IN A FIVE-MONTH-OLD INFANT. Pediatric Infectious Disease Journal, 1999, 18, 936-937.	1.1	3
268	More data from Australia on sensitivity to HPV vaccine. BMJ: British Medical Journal, 2009, 338, b26-b26.	2.4	3
269	Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults. PLoS ONE, 2016, 11, e0160446.	1.1	3
270	Pneumococcal vaccines â€“ past, present and future. Australian Prescriber, 2013, 36, 88-93.	0.5	3

#	Article	IF	Citations
271	Summary of national surveillance data on vaccine preventable diseases in Australia, 2012â€“2015. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	3
272	The changing epidemiology of measles in an era of elimination: lessons from health-care-setting transmissions of measles during an outbreak in New South Wales, Australia, 2012. Western Pacific Surveillance and Response Journal: WPSAR, 2016, 7, 12-20.	0.3	3
273	Australian mumps serosurvey 2012â€“2013: any cause for concern?. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	3
274	Australian vaccine preventable disease epidemiological review series: measles 2000-2011. Communicable Diseases Intelligence, 2015, 39, E1-9.	0.5	3
275	Back pain in a 4-year-old boy. Journal of Paediatrics and Child Health, 2000, 36, 275-276.	0.4	2
276	Influenza vaccines in healthy children. Lancet, The, 2005, 365, 2086.	6.3	2
277	Commentary on opinion pieces re Australian human papillomavirus vaccine policy. Sexual Health, 2010, 7, 242.	0.4	2
278	Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Medical Journal of Australia, 2017, 207, 395-396.	0.8	2
279	PhD thesis opposing immunisation: Failure of academic rigour with real-world consequences. Vaccine, 2019, 37, 1541-1545.	1.7	2
280	Influenza vaccination coverage in a population-based cohort of Australian-born Aboriginal and non-Indigenous older adults. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	2
281	Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000â€“2017. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	2
282	Pertussis burden and acellular pertussis vaccine effectiveness in high risk children. Vaccine, 2022, 40, 1376-1382.	1.7	2
283	Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998. Communicable Diseases Intelligence, 2000, 24, 276-7.	0.5	2
284	Is low immunisation coverage in inner urban areas of Australia due to low uptake or poor notification?. Australian Family Physician, 2003, 32, 1041-3.	0.5	2
285	Immunisation coverage annual report, 2011. Communicable Diseases Intelligence, 2013, 37, E291-312.	0.5	2
286	Immunisation coverage annual report, 2013. Communicable Diseases Intelligence, 2016, 40, E146-69.	0.5	2
287	Universal varicella vaccination. Medical Journal of Australia, 2005, 183, 277-279.	0.8	1
288	Update on childhood pneumococcal vaccination. Pediatric Health, 2008, 2, 351-365.	0.3	1

#	Article	IF	Citations
289	Epiglottitis: Going, going, but not gone yet. Journal of Paediatrics and Child Health, 2010, 46, 446-446.	0.4	1
290	HPV related surveillance activities in Australia. Vaccine, 2010, 28, 7453-7454.	1.7	1
291	Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Sao Paulo Medical Journal, 2012, 130, 133-133.	0.4	1
292	Assessing the effect of meningitis prevention and treatment. Lancet Infectious Diseases, The, 2014, 14, 780-781.	4.6	1
293	Immunisation Coverage Annual Report 2018. Communicable Diseases Intelligence (2018), 2021, 45, .	0.3	1
294	TheNSW Immunisation Strategy 2008â€“2011: how are we doing?. NSW Public Health Bulletin, 2010, 21, 193.	0.3	1
295	Tetanus Immunity and Epidemiology in Australia, 1993-2010. Infectious Disorders - Drug Targets, 2020, 20, 330-340.	0.4	1
296	Hib disease must be prevented. Medical Journal of Australia, 1994, 161, 451-452.	0.8	1
297	Diphtheria Immunity in Australia: Should we be Concerned?. Infectious Disorders - Drug Targets, 2020, 20, 323-329.	0.4	1
298	Hepatitis B Seroepidemiology in Australia, One Decade After Universal Vaccination of Infants and Adolescents. Infectious Disorders - Drug Targets, 2020, 20, 341-347.	0.4	1
299	Invasive Haemophilus influenzae type b disease. Australian Family Physician, 1993, 22, 1782-4, 1788-9.	0.5	1
300	The national measles surveillance strategy. The National Centre for Disease Control Measles Elimination Advisory Committee. Communicable Diseases Intelligence, 1999, 23, 41-50.	0.5	1
301	Influenza vaccination coverage in a population-based cohort of Australian-born Aboriginal and non-Indigenous older adults. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	1
302	Pneumocystis carinii pneumonia: Pitfalls of prophylaxis. Journal of Paediatrics and Child Health, 1998, 34, 477-479.	0.4	0
303	Comment. Journal of Paediatrics and Child Health, 2001, 37, 37-37.	0.4	0
304	Tdap: a new option for pertussis booster vaccination of seniors. Aging Health, 2012, 8, 449-455.	0.3	0
305	Margaret Anne Burgess. Medical Journal of Australia, 2016, 204, 389-391.	0.8	0
306	No Jab, No Pay and vaccine refusal in Australia: the jury is out. Medical Journal of Australia, 2017, 207, 407-407.	0.8	0

#	Article	IF	Citations
307	Extending Antenatal Pertussis Immunization to Second Trimester or At-Birth Pertussis Immunization of Premature Infants?â€"Reply. JAMA Pediatrics, 2019, 173, 295.	3.3	0
308	Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine, 2019, 37, 7534.	1.7	0
309	Challenges in Valuing Vaccine Prevention of Severe Early-Infant Infections. Clinical Infectious Diseases, 2020, 71, 1988-1989.	2.9	0
310	Bacille Calmetteâ€"GuÃ©rin vaccination site abscess: When is it a problem?. Journal of Paediatrics and Child Health, 2021, , .	0.4	0
311	Invasive pneumococcal disease. Humanities Research, 2013, 24, 142.	0.1	0
312	Cantu syndrome and hypopituitarism: implications for endocrine monitoring. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.2	0
313	Epidemiology and prevention of pneumococcal disease. Communicable Diseases Intelligence, 1997, 21, 41-6.	0.5	0
314	Surveillance of pneumococcal disease in Australian states and territories. Communicable Diseases Intelligence, 2000, 24, 93-5.	0.5	0